The cardiorenal syndrome and erythropoietin;Srčano-bubrežni sindrom i eritropoetin

Acta Medica Croatica

Volumn 62, Issue SUPPL. 1, 2008, Pages 21-31

  Kes, Petar ^a   Bašić Jukić, Nikolina ^a   Jurić, Ivana ^a   Bašić Kes, Vanja ^b  

^a KBC Zagreb   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Cardiorenal syndrome; Heart failure; Inflammation; Nitric oxide; Reactive oxygen species; Renal failure, anaemia; Renin angiotensin system; Sympatic nervous system

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; ERYTHROPOIETIN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE;

ADRENERGIC SYSTEM; ANEMIA; CARDIORENAL SYNDROME; CHRONIC KIDNEY FAILURE; DISEASE COURSE; HEART FAILURE; HEART FUNCTION; HEART PERFORMANCE; HUMAN; INFLAMMATION; KIDNEY FUNCTION; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; PHYSIOLOGY; SYNDROME;

ERYTHROPOIETIN; HEART FAILURE; HUMANS; KIDNEY FAILURE, CHRONIC; SYNDROME;

EID: 43249086511     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 2005; 26: 1117, 2005.
2. Jie KE, Verhaar MC. Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Renal Physiol 2006; 291: 932-944.
3. Kes P, Druško Crossed D sign, Šefer S. The natural history of myocardial disease in end-stage renal failure. Acta Clin Croat 1998; 37: 41-50.
4. Kes P, Ljutić D. Cardiovascular risk factors in end-stage renal disease. Acta Med Croat 1998; 52(Suppl 1): 1-10.
5. Hillege HL, Girbes AR, de Kam PJ, i sur. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203210.
6. Muntner P, He J, Hamm L, Loria Paul C, Whelton K. Renal Insufficiency and Subsequent Death Resulting from Cardiovascular Disease in the United States. J Am Soc Nephrol 2002; 13: 745-753
7. Felker GM, Adams KF Jr, Gattis WA, O'Connor CM. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 2004; 44: 959966.
8. Silverberg DS, Wexler D, Blum M, i sur. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35: 17371744.
9. Kazmi WH, Kausz AT, Khan S, i sur. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 2001; 38: 803812.
10. Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant 2003; 2: ii2ii6.
11. Kes P. Povoljni učinci liječenja bubrežne anemije u ranim stadijima kroničnog zatajenja bubrega. Liječ Vjesn 2002; 124: 108-9.
12. Kuriyama S, Tomonari H, Yoshida H, i sur. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176185.
13. Silverberg DS, Wexler D, Blum M, i sur. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35: 17371744.
14. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 2005; 26: 1117.
15. Pueyo ME, Gonzalez W, Nicoletti A, i sur. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000; 20: 645651.
16. Vallance P, Leone A, Calver A, Collier J, and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572575.
17. Katoh M, Egashira K, Usui M, i sur. Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ Res 1998; 83: 743751.
18. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, i sur. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 25242532.
19. Zukowska-Grojec Z. Neuropeptide Y. A novel sympathetic stress hormone and more. Ann N Y Acad Sci 1995; 771: 219233.
20. Kes P, Bobić I, Reiner Ž, Ratković-Gusić I. Učinak liječenja eritropoetinom na koncentraciju serumskih lipoproteina u hemodijaliziranih bolesnika. Liječ Vjesn 2002; 124: 146-150.
21. Kes P, Brunetta B. Treba li potpuno ispraviti anemiju u bolesnika s kroničnim zatajenjem bubrega? Liječ Vjesn 2002; 124: 225-7.
22. Jurić M, Rupčić V, Topuzović N, i sur. Hemodynamic changes and exercise tolerance in dialysis patients treated with erythropoietin. Nephrol Dial Transplant 1995; 10: 1398-1404.
23. Besarab A, Bolton WK, Browne JK, i sur. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584590.
24. Bašić Jukić N, Jurić I, Kes P.Liječenje željezom bolesnika na dijalizi. Acta Medica Croatica 2006; 60: 457-462.
25. Sengolge G, Horl WH, Sunder-Plassmann G. Intravenous iron therapy: well-tolerated, yet not harmless. Eur J Clin Invest 2005; 35, Suppl 3: 4651.
26. Corti MC, Guralnik JM, Salive ME, i sur. Serum iron level, coronary artery disease, and all-cause mortality in older men and women. Am J Cardiol 1997; 79: 120127.
27. Kes P, Brunetta B, Bašić-Jukić N. Je li eritropoetin samo promotor eritropoeze? Liječ Vjesn 2005; 127: 158-60.
28. Chong ZZ, Kang JQ, Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 2002; 22: 503514.
29. Macdougall IC and Cooper A. The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant 2002; 17, Suppl 1: 4852.
30. Figueroa YG, Chan AK, Ibrahim R, i sur. NF-kappaB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression. Exp Hematol 2002; 30: 14191427.
31. Clark RA, Valente AJ. Nuclear factor kappa B activation by NADPH oxidases. Mech Ageing Dev 2004; 125: 799810.
32. Bašić-Jukić N, Brunetta B, Blažev M, i sur. Erythrocytosis in a hemodialysis patient treated with iron sucrose. Acta clin Croat 2004; 43: 385-388.
33. Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 2004; 15: 524537.
34. Sertić J, Slaviček J, Bozina N, i sur. Cytokines and growth factors in mostly atherosclerotic patients on hemodialysis determined by biochip array technology. Clin Chem Lab Med 2007; 45: 1347-1352.
35. Kes P, Ljutić D, I Hrvatsko društvo zanefrologiju, dijalizu i transplantaciju.Smjernice za liječenje anemije u bolesnika s kroničnim zatajenjem bubrega. TIPKO Zagreb, svibanj 2007, str. 1-24.
36. Kes P, Bašić Jukić N, Jurić I, Ratković-Gusić I. Anemija nakon transplantacije bubrega. Liječ Vjesn 2007; 129: 101-102.
37. Kes P, Bašić-Jukić N, Jurić I. Uporaba eritropoetina u bolesnika s akutnim zatajenjem bubrega. Liječ Vjesn 2006; 128: 250-251.
38. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004; 9 (Suppl 5): 1830.
39. Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol Dial Transplant 1999; 14(Suppl 2): 22-28.
40. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005; 293: 9095.
41. Sae-Ung N, Matsushima T, Choi I, i sur. Role of NF-kappa B in regulation of apoptosis of erythroid progenitor cells. Eur J Haematol 2005; 74: 315323.
42. Gobert S, Duprez V, Lacombe C, Gisselbrecht S, Mayeux P. The signal transduction pathway of erythropoietin involves three forms of mitogen-activated protein (MAP) kinase in UT7 erythroleukemia cells. Eur J Biochem 1995; 234: 7583.
43. Ratajczak J, Majka M, Kijowski J, i sur. Biological significance of MAPK, AKT and JAK-STAT protein activation by various erythropoietic factors in normal human early erythroid cells. Br J Haematol 2001; 115: 195204.
44. Luo G, Yu-Lee L. Stat5b inhibits NFkappaB-mediated signaling. Mol Endocrinol 2000; 14: 114123.
45. Larsen L, Ropke C. Suppressors of cytokine signalling: SOCS. APMIS 2002; 110: 833844.
46. Wald MR, Borda ES, Sterin-Borda L. Mitogenic effect of erythropoietin on neonatal rat cardiomyocytes: signal transduction pathways. J Cell Physiol 1996; 167: 461468.
47. Sharples EJ, Patel N, Brown P, i sur. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004; 15: 211524.
48. Calvillo L, Latini R, Kajstura J, Leri A, i sur. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodelling. Proc Natl Acad Sci USA 2003; 100: 48024806.
49. Van der Meer P, Voors AA, Lipsic E, i sur. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004; 44: 6367.
50. Silvenberg DS, Wexler D, Sheps D, i sur. The effect of correction of mild anaemia in severe, resistant congestive heart failure using subcutaneous erythoropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37: 1775-80.
51. Namiuchi S, Kagaya Y, Ohta J, i sur. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005; 45: 1406-12.
52. Vesey DA, Cheung C, Pat B, i sur Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 2004; 19: 348355.
53. Fishbane S, Ragolia L, Palaia T, i sur. Cytoprotection by darbepoetin/epoetin alpha in pig tubular and mouse mesangial cells. Kidney Int 2004; 65: 452458.
54. Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol Renal Fluid Electrolyte Physiol 1994; 266: F360F366.
55. De Groot K, Bahlmann FH, Sowa J, i sur. Uremia causes endothelial progenitor cell deficiency. Kidney Int 2004; 66: 641646.
56. Marti HH, Bernaudin M, Petit E, Bauer C. Neuroprotection and angiogenesis: dual role of erythropoietin in brain ischemia. News Physiol Sci 2000; 15: 2259.
57. Beleslin-Cokic BB, Cokic VP, Yu X, i sur. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004; 104: 20732080.
58. Scalera F, Kielstein JT, Martens-Lobenhoffer J, i sur. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol 2005; 16: 892898.
59. Kanagy NL, Perrine MF, Cheung DK, Walker BR. Erythropoietin administration in vivo increases vascular nitric oxide synthase expression. J Cardiovasc Pharmacol 2003; 42: 527533.
60. Vaziri ND, Zhou XJ, Naqvi F, i sur. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol Endocrinol Metab 1996; 271: E113E122.
61. Yu X, Lin CS, Costantini F, Noguchi CT. The human erythropoietin receptor gene rescues erythropoiesis and developmental defects in the erythropoietin receptor null mouse. Blood 2001; 98: 475477.
62. Buemi M, Denuzzo G, Allegra A, i sur. Recombinant human erythropoietin inhibits the cutaneous vasodilatation induced by acetylcholine. Int J Microcirc Clin Exp 1995; 15: 283286.
63. Ludat K, Sommerburg O, Grune T, i sur. Oxidation parameters in complete correction of renal anemia. Clin Nephrol 2000; 53: S3035.
64. Choudhury TD, Das N, Chattopadhyay A, Datta AG. Effect of oxidative stress and erythropoietin on cytoskeletal protein and lipid organization in human erythrocytes. Pol J Pharmacol 1999; 51: 341350.
65. Fritschka E, Neumayer HH, Seddighi S, i sur. Effect of erythropoietin on parameters of sympathetic nervous activity in patients undergoing chronic haemodialysis. Br J Clin Pharmacol 1990; 30, Suppl 1: 135S138S.
66. Hand MF, Haynes WG, Johnstone HA, Anderton JL, Webb DJ. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 1995; 48: 806813.
67. Onoyama K, Hori K, Osato S, Fujishima M. Haemodynamic effect of recombinant human erythropoietin on hypotensive haemodialysis patients. Nephrol Dial Transplant 1991; 6: 562565.
68. Jandeleit K, Heintz B, Gross-Heitfeld E, i sur. Increased activity of the autonomic nervous system and increased sensitivity to angiotensin II infusion after therapy with recombinant human erythropoietin. Nephron 1990; 56: 220221.
69. Goicoechea M, Martin J, de Sequera P, i sur. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 1998; 54: 13371343.
70. Kumral A, Gonenc S, Acikgoz O, i sur. Erythropoietin increases glutathione peroxidase enzyme activity and decreases lipid peroxidation levels in hypoxic-ischemic brain injury in neonatal rats. Biol Neonate 2004; 87: 1518.
71. Alexander WS, Starr R, Fenner JE, i sur. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 1999; 98: 597608.
72. Allen DA, Breen C, Yaqoob MM, and Macdougall IC. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. J Investig Med 1999; 47: 204211.
73. Kes P, Bašić-Jukić N, Jurić I, Ratković-Gusić I. Ultračisti dijalizat: san ili java? Liječ Vjesn 2006; 128: 404-406.
74. 2+ mobilization in cultured rat vascular smooth-muscle cells. Nephrol Dial Transplant 2001; 16: 491499.
75. Kokot F, Wiecek A, Schmidt-Gayk H, i sur. Function of endocrine organs in hemodialyzed patients of long-term erythropoietin therapy. Artif Organs 1995; 19: 428435.
76. Kodama H, Fukuda K, Pan J, i sur. Biphasic activation of the JAK/STAT pathway by angiotensin II in rat cardiomyocytes. Circ Res 1998; 82: 244250.
77. Kes P. Significance of correction of renal anaemia with erythropoietin in haemodialyzed patients. Acta Med Croat 2005; 59(Suppl 1): 148-154.